Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions

被引：0
|
作者：
Huntemann, Niklas [1 ,2 ]
Mueller, Marc [1 ,2 ]
Masanneck, Lars [1 ,2 ]
Baumgart, Romy [3 ]
Axhausen, Franziska [3 ]
Wolff, Stephanie [3 ]
Kutsojannis, Bela [1 ,2 ]
Koelsche, Tristan [1 ,2 ]
Korsen, Melanie [1 ,2 ]
Pfeuffer, Steffen [3 ]
Meuth, Sven [1 ,2 ]
Pawlitzki, Marc [1 ,2 ]
机构：
[1] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Dusseldorf, Germany
[3] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Neurol, Giessen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O095/1249
引用
收藏
页码：90 / 91
页数：2
相关论文
共 50 条
  • [1] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [2] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S303 - S303
  • [3] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 457 - 457
  • [4] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [5] Efficacy and safety of natalizumab as escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, Norman
    Kiriaki, Kollia
    Katsarava, Zaza
    Woods, Sophia
    Give, Ezinne
    Diener, H.
    NEUROLOGY, 2008, 70 (11) : A90 - A90
  • [6] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [7] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [8] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [9] Efficacy and safety of natalizumab in children with highly active relapsing-remitting multiple sclerosis
    Karageorgiou, Klimentini E.
    Polyzoi, Maria
    Tzitzika, Moira
    Xatzi, Ioanna
    Alexoudi, Athanasia
    MULTIPLE SCLEROSIS, 2008, 14 : S51 - S51
  • [10] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
12345